Epizyme Inc. has closed a public offering of shares, raising $172.5 million to fund global development of the company's cancer treatment tazemetostat.
Cambridge, Mass.-based Epizyme closed two separate underwritten public offerings of 11.5 million common shares and 350,000 non-voting Series A convertible preferred stock, according to a March 12 press release.
Underwriters fully exercised their option to purchase additional shares in the offering. Each share was offered at $11.50, while each Series A stock was $115 apiece.
The company said net proceeds from the offering will be used to fund global development of tazemetostat outside of Japan. The medicine is under development for epithelioid sarcoma, a rare type of soft tissue cancer, and follicular lymphoma, a type of non-Hodgkin lymphoma. Remaining funds will be used to identify other drug candidates and for working capital and general corporate purposes.
Joint book-running managers on the offering were Jefferies, Citigroup and Cowen, while Wedbush PacGrow acted as lead manager and H.C. Wainwright & Co. as co-manager.